Zai Lab Ltd

The U.S. Food and Drug Administration has granted Orphan Drug Designation to Zai Lab's zocilurtatug pelitecan, a potential first-in-class DLL3-targeting antibody-drug conjugate, for the treatment of neuroendocrine carcinomas. Neuroendocrine carcinomas are aggressive malignancies with poor prognoses and limited treatment options, and there are currently no approved targeted therapies for previously treated patients. This designation follows the European Medicines Agency's Orphan Drug Designation for zocilurtatug pelitecan in pulmonary neuroendocrine carcinomas, reinforcing its first-in-class potential across a range of neuroendocrine carcinomas. The FDA had previously granted Fast Track designation for extrapulmonary neuroendocrine carcinomas and both Fast Track and Orphan Drug Designation for small cell lung cancer, the most significant pulmonary neuroendocrine carcinoma. Orphan Drug Designation provides development incentives including a waiver of the Prescription Drug User Fee Act registration application fee, tax credits for certain clinical trials, and the potential for seven years of U.S. market exclusivity upon approval.

Z.AI, the Chinese artificial intelligence company formerly known as Zhipu, has completed construction of a massive 1-gigawatt data center powered entirely by Chinese-made chips. The facility has started partial operations and is designed to provide the computing capacity needed to develop Z.AI's most advanced GLM systems. Its power capacity is roughly equivalent to the electricity required to supply 750,000 homes at any given moment. Z.AI has also built or operated several computing clusters containing more than 10,000 chips each, suggesting the company is expanding its infrastructure as competition among Chinese AI developers intensifies. The project represents an important milestone in China's effort to reduce reliance on restricted silicon from NVIDIA, and investors may view the facility as a major test of whether China's domestic chip industry can support increasingly advanced AI models over the longer term.

Zai Lab announced that the European Medicines Agency granted orphan drug designation to zocilurtatug pelitecan, a potential first-in-class DLL3-targeting antibody-drug conjugate for pulmonary neuroendocrine carcinomas. The designation followed a positive recommendation from the EMA's Committee for Orphan Medicinal Products, recognizing significant unmet need in this disease area. The decision was supported by early clinical findings in relapsed or refractory extensive-stage small cell lung cancer, suggesting zocilurtatug pelitecan may provide durable responses and potential advantages over existing therapies. The designation may provide regulatory benefits including development incentives and possible market exclusivity.